↓ Skip to main content

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analy…

Overview of attention for article published in Breast Cancer Research and Treatment, November 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

blogs
1 blog
policy
1 policy source

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
72 Mendeley
Title
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
Published in
Breast Cancer Research and Treatment, November 2013
DOI 10.1007/s10549-013-2778-5
Pubmed ID
Authors

Thomas Bachelot, Rachael McCool, Steven Duffy, Julie Glanville, Danielle Varley, Kelly Fleetwood, Jie Zhang, Guy Jerusalem

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 71 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 22%
Student > Ph. D. Student 12 17%
Other 8 11%
Student > Master 6 8%
Student > Bachelor 5 7%
Other 13 18%
Unknown 12 17%
Readers by discipline Count As %
Medicine and Dentistry 29 40%
Agricultural and Biological Sciences 8 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Biochemistry, Genetics and Molecular Biology 4 6%
Economics, Econometrics and Finance 4 6%
Other 9 13%
Unknown 13 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2019.
All research outputs
#3,768,078
of 22,731,677 outputs
Outputs from Breast Cancer Research and Treatment
#672
of 4,649 outputs
Outputs of similar age
#44,195
of 302,026 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#17
of 73 outputs
Altmetric has tracked 22,731,677 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,649 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 302,026 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.